Atlas Venture Life Science Advisors’s Xilio Therapeutics XLO Stock Holding History

Atlas Venture Life Science Advisors’s Portfolio XLO Stock Details XLO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-70,922	Closed	-$1.07M	–	16
2024 Q1	$1.07M	Sell	70,922 -126,174	-64%	-$1.22M	0.1%	15
2023 Q4	$1.52M	Hold	197,096	–	–	0.18%	15
2023 Q3	$5.82M	Hold	197,096	–	–	0.9%	13
2023 Q2	$7.23M	Hold	197,096	–	–	0.9%	12
2023 Q1	$8.75M	Hold	197,096	–	–	1.18%	12
2022 Q4	$7.42M	Hold	197,096	–	–	0.89%	12
2022 Q3	$8.03M	Hold	197,096	–	–	0.89%	12
2022 Q2	$8.06M	Hold	197,096	–	–	1.35%	11
2022 Q1	$19.5M	Hold	197,096	–	–	2.47%	10
2021 Q4	$44.1M	Buy	+197,096	New	+$47M	4.06%	8

Other funds holding XLO

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

TPC

Takeda Pharmaceutical Company Tokyo, Japan $16.4M AUM 195.92% 1-Year Est. Return

RVM

RiverVest Venture Management St. Louis, Missouri $6.84M AUM 7.71% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

Atlas Venture Life Science Advisors's XLO Position: Q2 2024 in Review

Atlas Venture Life Science Advisors sold out of Xilio Therapeutics (XLO) in Q2 2024, closing a stake of 70,922 shares — an estimated $1.07M sold.

Atlas Venture Life Science Advisors first reported a position in XLO in Q4 2021 and held it in 10 quarters. The position peaked at $44.1M in Q4 2021. 31 funds tracked by Wall St. Rank hold XLO as of Q2 2024.

Atlas Venture Life Science Advisors reported no remaining Xilio Therapeutics position as of Q2 2024 after selling out during the quarter.
Atlas Venture Life Science Advisors sold 70,922 Xilio Therapeutics shares in Q2 2024, an estimated $1.07M.
Atlas Venture Life Science Advisors first reported a position in Xilio Therapeutics in Q4 2021 and held it in 10 quarters.
Atlas Venture Life Science Advisors's Xilio Therapeutics position peaked at $44.1M in Q4 2021.
31 funds tracked by Wall St. Rank held Xilio Therapeutics as of Q2 2024.

Based on Atlas Venture Life Science Advisors's 13F filing for Q2 2024, filed 9 Aug 2024.